Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)

20260 citationsJournal Articlegold Open Access

Authors

NCT05290038.

Partnerships for the goals

Published in: Cancer Immunology Immunotherapy

Volume 75, Issue 4

Field-Weighted Citation Impact: 0.00